Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
about
A Convenient Truth: Cost of Medications Need Not Be a Barrier to Hepatitis B TreatmentImportance of Drug Pharmacokinetics at the Site of ActionThe preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA.The promise and pitfalls of long-acting injectable agents for HIV prevention.Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine ModelA Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure ProphylaxisCreation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-ThiacytidineA Review of HIV Pre-Exposure Prophylaxis: The Female PerspectiveThe future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.Long-Acting Antiretrovirals: Where Are We now?Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men.Application of electrospun fibers for female reproductive health.Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.Current and future contraceptive options for women living with HIV.Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque modelLong-Acting HIV Treatment and Prevention: Closer to the Threshold.Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.Creation of a long-acting nanoformulated dolutegravir.Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.Emerging reverse transcriptase inhibitors for HIV-1 infection.Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals.Development of peptide inhibitors of HIV transmission.Harnessing nanostructured systems for improved treatment and prevention of HIV diseasePerspectives of South African youth in the development of an implant for HIV preventionWho Wants to Switch? Gauging Patient Interest in Novel Antiretroviral Therapies
P2860
Q28386440-5197D4BF-FF9F-4CD6-984D-134D4A30E569Q33648045-ACBB6EC6-F248-4390-BDEC-FCC3B8D1AB00Q36348296-09DDF82B-25D4-48A8-921A-D41CC81981C7Q36561375-04C4B45E-305A-431C-969A-B4B4BBFF6072Q36933498-A63DB11F-1BF9-4344-840E-05A04ACC3C55Q36968405-9E3A91C0-4672-4CEC-8FE6-E7B98D6C82A6Q37639081-31C5988F-F1C3-46C6-A153-C9C002AA96EAQ38672579-5A94E61E-BCE4-4582-929A-B2AAD6E75CF4Q38742497-FFC237B1-985C-4261-8CD8-1AE3C3227634Q38902077-CC856BA9-73D0-41CC-A619-2D5A18AF1FF8Q39215169-BC8A3B73-DD51-42B4-B9F0-73E270440989Q39259966-5851CF30-EF6C-44DA-9D6F-69738E442D50Q39301728-4C088CD3-B475-4AF3-B296-AE4E0EC61F8EQ39371494-7BFA3E4C-5604-415D-8010-FE5BB552B33EQ40048203-C6337A60-3390-473B-8BDF-FB1A62EA1216Q40465731-120CB713-094D-4B6A-B03F-F286CBE9323FQ41923505-1933AA21-2197-474E-A2CE-3F1DFD1F1884Q42334096-83844339-1169-469B-9CD9-AC753F917E38Q46843041-72553B86-C9C6-476E-9164-C16FA667078BQ47603651-37C9175C-636A-4383-A82C-2A412E079F74Q47806688-143EA20D-6B0F-4208-8040-3E05A6F2ECFBQ50051618-53695D0B-FC07-4CC2-BF3A-B7B53A6695A5Q50059498-29D8D527-54BF-48BE-94E7-43141F2724E9Q53686168-A1641E38-14B2-487E-BD59-9CEE1F92980EQ54253541-55177C78-F819-4AA7-900F-897F96C7BA65Q55317261-C86908B1-A8FD-4B91-BADB-17A29DCB9C56Q56992437-6D1B2593-A3EC-4A6C-936F-DD71B6990B53Q57172735-5C667D9D-93BE-4894-9EFC-6DC6CF53FCE7Q58583047-070E62DA-C67F-4751-B11D-BF682EE00B4F
P2860
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacokinetics of long-actin ...... l implant for HIV prophylaxis.
@ast
Pharmacokinetics of long-actin ...... l implant for HIV prophylaxis.
@en
type
label
Pharmacokinetics of long-actin ...... l implant for HIV prophylaxis.
@ast
Pharmacokinetics of long-actin ...... l implant for HIV prophylaxis.
@en
prefLabel
Pharmacokinetics of long-actin ...... l implant for HIV prophylaxis.
@ast
Pharmacokinetics of long-actin ...... l implant for HIV prophylaxis.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of long-actin ...... l implant for HIV prophylaxis.
@en
P2093
Christine S Miller
Craig W Hendrix
Flora Yang
John A Moss
Manjula Gunawardana
Marc M Baum
Mariana Remedios-Chan
Mark A Marzinke
Martin Beliveau
Rob Fanter
P2860
P304
P356
10.1128/AAC.00656-15
P407
P577
2015-04-20T00:00:00Z